Corvus Pharmaceuticals (CRVS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
24 Apr, 2026Voting matters and shareholder proposals
Election of two Class I Directors for terms expiring at the 2029 annual meeting is proposed, with board recommendation to vote FOR.
Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2026, recommended FOR.
Advisory vote to approve compensation of named executive officers, with board recommendation to vote FOR.
Board of directors and corporate governance
Board recommends the election of two director nominees to serve until the 2029 annual meeting.
Executive compensation and say-on-pay
Shareholders are asked to approve, on a non-binding basis, the compensation of named executive officers.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Corvus Pharmaceuticals
- Lead asset soquelitinib advances in oncology and immunology with strong IP and cash runway.CRVS
Goldman Sachs 47th Annual Global Healthcare Conference 20268 Jun 2026 - Durable efficacy and safety demonstrated in immune diseases, with broad clinical expansion underway.CRVS
Jefferies Global Healthcare Conference 20263 Jun 2026 - Soquelitinib achieved durable efficacy, safety, and immune rebalancing in atopic dermatitis.CRVS
Study update20 May 2026 - Q1 2026 net loss of $13.7M, $236.7M cash, clinical advances, runway into Q2 2028.CRVS
Q1 20267 May 2026 - Virtual meeting to elect directors, ratify auditor, and approve executive pay, with focus on governance.CRVS
Proxy filing24 Apr 2026 - Soquelitinib showed robust efficacy, safety, and immune modulation in atopic dermatitis Phase 1.CRVS
Study result12 Apr 2026 - Strong clinical and financial momentum with soquelitinib, supporting pipeline expansion and durability.CRVS
Q4 202512 Mar 2026 - Soquelitinib shows robust efficacy and safety in AD, targeting broad immune disease markets.CRVS
Corporate presentation12 Mar 2026 - Soquelitinib shows robust efficacy and safety in atopic dermatitis, targeting a major unmet need.CRVS
Corporate presentation26 Feb 2026